Island Pharmaceuticals (ASX:ILA) adds Chikungunya to ISLA-101 patent as Asia becomes the real prize

Singapore protection through 2034 quietly widens the partnering pitch beyond Dengue and into a second mosquito-borne market

Patent announcements usually get filed away as housekeeping. This one from Island Pharmaceuticals (ASX:ILA) deserves a closer look, because it quietly changes what ISLA-101 can be sold as.

The Intellectual Property Office of Singapore has granted a patent covering the use of ISLA-101 as a standalone antiviral for flavivirus infections, including Dengue, and for Chikungunya virus. The patent is owned by Monash University and sits inside Island’s exclusive licence. Protection runs until 16 April 2034, giving the company nearly eight years of commercial exclusivity in that market.

Two things are new here, not one. Singapore is a fresh jurisdiction inside the region where mosquito-borne viral disease actually kills people. And the claim covers Chikungunya, which was not previously part of the ISLA-101 narrative most investors were carrying in their heads.

For a company whose story to date has centred on Galidesivir’s biodefence pathway and ISLA-101’s Dengue Phase 2a data, adding a second indication with the same delivery format and the same mosquito vector is a low-cost widening of the addressable market. That is what we think today’s release is really doing.

Chikungunya turns ISLA-101 from a one-disease asset into a platform pitch

Chikungunya causes debilitating joint pain, spreads through the same Aedes mosquitoes that carry Dengue, and has no widely available antiviral treatment. Outbreaks have hit Reunion, India, the Americas and parts of Southeast Asia in recent years, with the WHO flagging the disease as a growing global concern.

For ISLA-101, the practical value of the Chikungunya claim is that a partner buying the Dengue rights now sees a second commercial lane without paying for a second molecule. Same patient population, same distribution channel, same public health buyers.

We think this is the quiet reason the announcement matters. Partnering conversations are shaped by the breadth of the label a licensee thinks they can eventually get, and the IP estate is what defines that breadth on day one.

Singapore is small on its own but strategic as an Asia beachhead

Singapore is not the volume market. Its value is different. It sits at the centre of ASEAN’s regulatory and commercial infrastructure, with the Health Sciences Authority often used as a reference regulator across the region.

Dengue is endemic across Southeast Asia, and Chikungunya outbreaks in India and Indonesia have pushed governments to look for antiviral options rather than relying solely on vector control. A patent granted in Singapore reads as a signal to potential Asia-Pacific partners that Island has done the work to protect commercial exclusivity where the disease actually lives.

The skeptical read is that a single-country patent grant does not on its own change the economics. That is fair. But it slots into a broader IP mosaic that already includes US protection for Galidesivir and the Monash-licensed method-of-viral-inhibition family for ISLA-101.

The dual-asset story keeps quietly getting stronger

Island now has two distinct programs each accumulating regulatory and IP milestones on their own timelines. Galidesivir is inside the GMP manufacturing campaign with PI Health Sciences, aiming at the Animal Rule pathway for Marburg and carrying optionality against Ebola.

ISLA-101 sits on the other side of the portfolio, with Phase 2a Dengue data already in hand and an IP estate that now extends into Chikungunya and into Singapore. The two programs share almost no risk correlation, which is unusual for a micro-cap biotech.

For investors, that diversification matters. A setback on one asset does not automatically end the story, and a partnering deal on either side would revalue the equity.

The Investors Takeaway for Island Pharmaceuticals

On its own, a Singapore patent grant does not move the needle. But the pattern is what we would watch. Island keeps quietly extending the commercial fence line around ISLA-101 while Galidesivir works through GMP.

The next real catalyst on ISLA-101 will be either a partnering signal or Phase 2b progression. When that arrives, the value of today’s patent grant will show up in the deal terms rather than in the share price today. Investors can read our previous coverage of Island’s Galidesivir progress at stocksdownunder.

We think the market is still pricing Island as a single-asset biodefence story. The ISLA-101 IP estate suggests that framing is already out of date.